PhD in Health Technology Assessment
Expenditures on oncology drugs are sharply rising due to the introduction of many new/innovative drugs and high drug prices. There are doubts about whether these treatments and associated costs always benefit patients and healthcare systems. An important question is whether an HTA lifecycle approach could contribute to better decision-making and more controlled and efficient/affordable access … Read more